AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
agomelatine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 99 | 138112-76-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an antidepressant, it works by stimulating the MT1 and MT2 receptors, which are normally activated by melatonin, and also by blocking the 5-HT2C receptors, which are normally activated by the neurotransmitter 5-hydroxytryptamine
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| fu (Fraction unbound in plasma) | 0.07 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| BA (Bioavailability) | 5 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,JAK2,KIT,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 48 | |||
| kinase-selectivity-class | AXL,BRAF,GRK2,PDK4 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 19, 2009 | EMA | Les Laboratoires Servier |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Intentional overdose | 77.57 | 29.67 | 45 | 3036 | 93789 | 90531577 |
| Serotonin syndrome | 75.48 | 29.67 | 33 | 3048 | 37854 | 90587512 |
| Extrapyramidal disorder | 63.33 | 29.67 | 23 | 3058 | 16280 | 90609086 |
| Suicidal ideation | 59.90 | 29.67 | 35 | 3046 | 73820 | 90551546 |
| Intentional self-injury | 56.63 | 29.67 | 25 | 3056 | 29309 | 90596057 |
| Drug interaction | 55.51 | 29.67 | 57 | 3024 | 276396 | 90348970 |
| Suicide attempt | 54.04 | 29.67 | 33 | 3048 | 75366 | 90550000 |
| Lipoedema | 50.71 | 29.67 | 9 | 3072 | 340 | 90625026 |
| Selective eating disorder | 49.86 | 29.67 | 12 | 3069 | 2041 | 90623325 |
| Completed suicide | 48.86 | 29.67 | 40 | 3041 | 145018 | 90480348 |
| Toxicity to various agents | 44.93 | 29.67 | 52 | 3029 | 287794 | 90337572 |
| Serum serotonin increased | 40.84 | 29.67 | 7 | 3074 | 215 | 90625151 |
| Fistula discharge | 40.61 | 29.67 | 9 | 3072 | 1066 | 90624300 |
| Salivary hypersecretion | 39.72 | 29.67 | 14 | 3067 | 9078 | 90616288 |
| Spinal cord disorder | 37.24 | 29.67 | 9 | 3072 | 1556 | 90623810 |
| Tracheal injury | 35.58 | 29.67 | 6 | 3075 | 167 | 90625199 |
| Accelerated hypertension | 35.40 | 29.67 | 7 | 3074 | 477 | 90624889 |
| Hyponatraemia | 35.15 | 29.67 | 32 | 3049 | 133506 | 90491860 |
| Bladder spasm | 34.92 | 29.67 | 9 | 3072 | 2021 | 90623345 |
| Clonus | 33.55 | 29.67 | 11 | 3070 | 5739 | 90619627 |
| Spinal pain | 32.24 | 29.67 | 14 | 3067 | 15753 | 90609613 |
| Urinary tract infection enterococcal | 31.39 | 29.67 | 9 | 3072 | 3007 | 90622359 |
| Urinary incontinence | 30.95 | 29.67 | 18 | 3063 | 37548 | 90587818 |
| Overdose | 30.65 | 29.67 | 32 | 3049 | 157677 | 90467689 |
| Psychiatric decompensation | 30.45 | 29.67 | 8 | 3073 | 1935 | 90623431 |
| Lividity | 30.42 | 29.67 | 6 | 3075 | 403 | 90624963 |
| Sleep deficit | 30.36 | 29.67 | 7 | 3074 | 989 | 90624377 |
| Enuresis | 30.29 | 29.67 | 9 | 3072 | 3405 | 90621961 |
| Myelopathy | 30.21 | 29.67 | 9 | 3072 | 3435 | 90621931 |
| Endometrial cancer | 29.79 | 29.67 | 9 | 3072 | 3603 | 90621763 |
| Bradycardia neonatal | 29.72 | 29.67 | 7 | 3074 | 1086 | 90624280 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyperaesthesia | 56.36 | 36.92 | 17 | 1640 | 5935 | 42613743 |
| Anorgasmia | 55.33 | 36.92 | 12 | 1645 | 1125 | 42618553 |
| Tachycardia | 50.23 | 36.92 | 37 | 1620 | 101050 | 42518628 |
| Drug interaction | 37.88 | 36.92 | 49 | 1608 | 266950 | 42352728 |
| Reflux nephropathy | 37.54 | 36.92 | 5 | 1652 | 21 | 42619657 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug interaction | 101.95 | 29.07 | 118 | 4807 | 500065 | 110084309 |
| Tachycardia | 81.93 | 29.07 | 73 | 4852 | 226572 | 110357802 |
| Intentional overdose | 71.69 | 29.07 | 54 | 4871 | 132447 | 110451927 |
| Suicide attempt | 66.97 | 29.07 | 47 | 4878 | 103347 | 110481027 |
| Amaurosis fugax | 64.34 | 29.07 | 16 | 4909 | 2374 | 110582000 |
| Serotonin syndrome | 63.52 | 29.07 | 37 | 4888 | 59116 | 110525258 |
| Anorgasmia | 54.41 | 29.07 | 13 | 4912 | 1633 | 110582741 |
| Ocular discomfort | 48.02 | 29.07 | 17 | 4908 | 8516 | 110575858 |
| Somnolence | 47.18 | 29.07 | 62 | 4863 | 297387 | 110286987 |
| Urinary tract disorder | 46.09 | 29.07 | 15 | 4910 | 5829 | 110578545 |
| Head discomfort | 44.14 | 29.07 | 20 | 4905 | 18980 | 110565394 |
| Drug level increased | 43.82 | 29.07 | 27 | 4898 | 47692 | 110536682 |
| Intentional self-injury | 39.08 | 29.07 | 23 | 4902 | 37406 | 110546968 |
| Hyperaesthesia | 39.02 | 29.07 | 17 | 4908 | 14710 | 110569664 |
| Hyponatraemia | 38.63 | 29.07 | 48 | 4877 | 217605 | 110366769 |
| Haemorrhagic stroke | 36.80 | 29.07 | 16 | 4909 | 13773 | 110570601 |
| Extrapyramidal disorder | 36.21 | 29.07 | 20 | 4905 | 28847 | 110555527 |
| Suicidal ideation | 35.35 | 29.07 | 31 | 4894 | 93906 | 110490468 |
| Serum serotonin increased | 35.16 | 29.07 | 7 | 4918 | 375 | 110583999 |
| Anhedonia | 35.08 | 29.07 | 16 | 4909 | 15412 | 110568962 |
| Tracheal injury | 32.07 | 29.07 | 6 | 4919 | 231 | 110584143 |
| Lipoedema | 31.78 | 29.07 | 6 | 4919 | 243 | 110584131 |
| Asthenia | 30.56 | 29.07 | 83 | 4842 | 688916 | 109895458 |
| Drug ineffective | 29.94 | 29.07 | 140 | 4785 | 1520400 | 109063974 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06AX22 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D006993 | Hypnotics and Sedatives |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
Related Drugs by ATC class:
N06AX Other antidepressants 28 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Major depressive disorder | indication | 370143000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.7 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | GPCR | ANTAGONIST | Ki | 6.20 | IUPHAR | DRUG LABEL | |||
| Melatonin receptor type 1A | GPCR | AGONIST | Ki | 10.22 | CHEMBL | DRUG LABEL | |||
| Melatonin receptor type 1B | GPCR | AGONIST | Ki | 10 | CHEMBL | DRUG LABEL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 5.40 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2B | GPCR | ANTAGONIST | Ki | 6.60 | IUPHAR | ||||
| Melatonin receptor | GPCR | Ki | 10 | CHEMBL | |||||
| Melatonin receptor | GPCR | Ki | 9.28 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D02578 | KEGG_DRUG |
| C0971637 | UMLSCUI |
| CHEBI:134990 | CHEBI |
| CHEMBL10878 | ChEMBL_ID |
| DB06594 | DRUGBANK_ID |
| C084711 | MESH_SUPPLEMENTAL_RECORD_UI |
| 82148 | PUBCHEM_CID |
| 198 | IUPHAR_LIGAND_ID |
| 7392 | INN_ID |
| 137R1N49AD | UNII |
| AWY | PDB_CHEM_ID |
| 013126 | NDDF |
| 698012009 | SNOMEDCT_US |
| 702952002 | SNOMEDCT_US |
| 137R1N49AD | INXIGHT DRUGS |
Pharmaceutical products:
None